304 related articles for article (PubMed ID: 19481229)
1. Effect of red wine on urinary protein, 8-hydroxydeoxyguanosine, and liver-type fatty acid-binding protein excretion in patients with diabetic nephropathy.
Nakamura T; Fujiwara N; Sugaya T; Ueda Y; Koide H
Metabolism; 2009 Aug; 58(8):1185-90. PubMed ID: 19481229
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.
Nakamura T; Inoue T; Sugaya T; Kawagoe Y; Suzuki T; Ueda Y; Koide H; Node K
Am J Hypertens; 2007 Nov; 20(11):1195-201. PubMed ID: 17954367
[TBL] [Abstract][Full Text] [Related]
3. Study of urinary 8-hydroxydeoxyguanosine as a biomarker of oxidative DNA damage in diabetic nephropathy patients.
Xu GW; Yao QH; Weng QF; Su BL; Zhang X; Xiong JH
J Pharm Biomed Anal; 2004 Sep; 36(1):101-4. PubMed ID: 15351053
[TBL] [Abstract][Full Text] [Related]
4. Urinary fatty acids and liver-type fatty acid binding protein in diabetic nephropathy.
Sasaki H; Kamijo-Ikemori A; Sugaya T; Yamashita K; Yokoyama T; Koike J; Sato T; Yasuda T; Kimura K
Nephron Clin Pract; 2009; 112(3):c148-56. PubMed ID: 19390215
[TBL] [Abstract][Full Text] [Related]
5. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy.
Katavetin P; Eiam-Ong S; Suwanwalaikorn S
J Med Assoc Thai; 2006 Feb; 89(2):170-7. PubMed ID: 16579002
[TBL] [Abstract][Full Text] [Related]
6. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy.
Shimoike T; Inoguchi T; Umeda F; Nawata H; Kawano K; Ochi H
Metabolism; 2000 Aug; 49(8):1030-5. PubMed ID: 10954022
[TBL] [Abstract][Full Text] [Related]
7. Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy.
Nakamura T; Sugaya T; Node K; Ueda Y; Koide H
Am J Kidney Dis; 2006 Mar; 47(3):439-44. PubMed ID: 16490622
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy.
Ogawa S; Mori T; Nako K; Ito S
Hypertens Res; 2008 Jun; 31(6):1147-55. PubMed ID: 18716362
[TBL] [Abstract][Full Text] [Related]
9. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy.
Nakamura T; Sugaya T; Kawagoe Y; Ueda Y; Osada S; Koide H
Diabetes Care; 2005 Nov; 28(11):2728-32. PubMed ID: 16249547
[TBL] [Abstract][Full Text] [Related]
10. Oral adsorbent AST-120 ameliorates tubular injury in chronic renal failure patients by reducing proteinuria and oxidative stress generation.
Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Suzuki T; Ueda Y; Yamagishi S
Metabolism; 2011 Feb; 60(2):260-4. PubMed ID: 20189611
[TBL] [Abstract][Full Text] [Related]
11. Effect of erythropoietin on urinary liver-type fatty-acid-binding protein in patients with chronic renal failure and anemia.
Nakamura T; Sugaya T; Kawagoe Y; Suzuki T; Ueda Y; Koide H
Am J Nephrol; 2006; 26(3):276-80. PubMed ID: 16772708
[TBL] [Abstract][Full Text] [Related]
12. Urinary excretion of fatty acid-binding proteins in idiopathic membranous nephropathy.
Hofstra JM; Deegens JK; Steenbergen EJ; Wetzels JF
Nephrol Dial Transplant; 2008 Oct; 23(10):3160-5. PubMed ID: 18403431
[TBL] [Abstract][Full Text] [Related]
13. Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy.
Nakamura T; Fujiwara N; Sato E; Ueda Y; Sugaya T; Koide H
Kidney Blood Press Res; 2010; 33(3):213-20. PubMed ID: 20588058
[TBL] [Abstract][Full Text] [Related]
14. Reproducibility of renal function measurements in adult men with diabetic nephropathy: research and clinical implications.
Agarwal R
Am J Nephrol; 2007; 27(1):92-100. PubMed ID: 17284896
[TBL] [Abstract][Full Text] [Related]
15. Effects of NADPH oxidase inhibitor on diabetic nephropathy in OLETF rats: the role of reducing oxidative stress in its protective property.
Nam SM; Lee MY; Koh JH; Park JH; Shin JY; Shin YG; Koh SB; Lee EY; Chung CH
Diabetes Res Clin Pract; 2009 Feb; 83(2):176-82. PubMed ID: 19111363
[TBL] [Abstract][Full Text] [Related]
16. Cigarette smoking affects urinary liver-type fatty acid-binding protein concentration in patients with early diabetic nephropathy.
Nakamura T; Sugaya T; Koide H
Diabetes Care; 2006 Jul; 29(7):1717. PubMed ID: 16801619
[No Abstract] [Full Text] [Related]
17. Urinary dopamine, noradrenaline and adrenaline in type 2 diabetic patients with and without nephropathy.
Murabayashi S; Baba T; Tomiyama T; Takebe K
Horm Metab Res; 1989 Jan; 21(1):27-32. PubMed ID: 2925152
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic implications of urinary liver-type fatty acid-binding protein and 8-hydroxy-2'-deoxyguanosine in forensic autopsy cases.
Kashiwagi M; Sugimura T; Matsusue A; Hara K; Waters B; Kubo S
Leg Med (Tokyo); 2013 May; 15(3):140-4. PubMed ID: 23273867
[TBL] [Abstract][Full Text] [Related]
19. Effects of aerobic exercise on microalbuminuria and enzymuria in type 2 diabetic patients.
Lazarevic G; Antic S; Vlahovic P; Djordjevic V; Zvezdanovic L; Stefanovic V
Ren Fail; 2007; 29(2):199-205. PubMed ID: 17365936
[TBL] [Abstract][Full Text] [Related]
20. Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy.
Nakamura T; Inoue T; Fujiwara N; Kawagoe Y; Sugaya T; Ueda Y; Koide H; Node K
Clin Nephrol; 2008 Nov; 70(5):385-92. PubMed ID: 19000538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
